Prevalence of undiagnosed glucose intolerance and type 2 diabetes in patients with moderate-to-severe obstructive sleep apnea syndrome.


Journal

Sleep & breathing = Schlaf & Atmung
ISSN: 1522-1709
Titre abrégé: Sleep Breath
Pays: Germany
ID NLM: 9804161

Informations de publication

Date de publication:
Dec 2020
Historique:
received: 11 08 2019
accepted: 29 11 2019
revised: 26 11 2019
pubmed: 16 12 2019
medline: 24 11 2021
entrez: 16 12 2019
Statut: ppublish

Résumé

Overweight and obesity are major causal factors for obstructive sleep apnea syndrome (OSAS), providing insight into why one third of patients with OSAS suffer from diabetes mellitus and another third from glucose intolerance. However, a significant proportion of the general population remains undiagnosed for glucose metabolism disorders. The primary aim of this study was to establish the prevalence of known and newly diagnosed glucose metabolism disorders in patients with moderate and severe OSAS referred to the sleep lab for continuous positive airway pressure (CPAP) therapy. We prospectively included consecutive patients with moderate or severe OSAS referred for CPAP therapy. A fasting blood sample was collected to determine glycosylated hemoglobin (HbA1c), glucose, and homeostatic model assessment (HOMA) index. Baseline demographic data and medication intake were recorded. Of 280 consecutive patients (70% men, mean ± SD body mass index 33 ± 7 kg/m In this population of overweight and obese patients with moderate and severe OSAS, 66% of patients had diabetes or glucose intolerance and 28% were newly diagnosed. Diabetes and glucose intolerance were not related to OSAS severity, contrary to insulin resistance. These data suggest that there is value in systematic screening for glucose metabolism disorders in all patients with moderate and severe OSAS.

Identifiants

pubmed: 31838624
doi: 10.1007/s11325-019-01989-y
pii: 10.1007/s11325-019-01989-y
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1389-1395

Auteurs

Marie Bruyneel (M)

Department of Pulmonary Medicine, CHU Saint-Pierre, Brussels, Belgium. marie_bruyneel@stpierre-bru.be.
Université Libre de Bruxelles (ULB), Brussels, Belgium. marie_bruyneel@stpierre-bru.be.

Pierre Kleynen (P)

Université Libre de Bruxelles (ULB), Brussels, Belgium.
Department of Endocrinology, CHU Saint-Pierre, Brussels, Belgium.

Kris Poppe (K)

Université Libre de Bruxelles (ULB), Brussels, Belgium.
Department of Endocrinology, CHU Saint-Pierre, Brussels, Belgium.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH